.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Boehringer Ingelheim
Medtronic
Express Scripts
Cerilliant
QuintilesIMS
Federal Trade Commission
Julphar
Accenture
Deloitte

Generated: December 17, 2017

DrugPatentWatch Database Preview

Sunovion Company Profile

« Back to Dashboard

What is the competitive landscape for SUNOVION, and what generic alternatives to SUNOVION drugs are available?

SUNOVION has nine approved drugs.

There are forty-four US patents protecting SUNOVION drugs.

There are five hundred and sixty-nine patent family members on SUNOVION drugs in forty-eight countries and forty-four supplementary protection certificates in fourteen countries.

Summary for Sunovion

International Patents:569
US Patents:44
Tradenames:9
Ingredients:9
NDAs:9
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sunovion Pharms IncLATUDAlurasidone hydrochlorideTABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► Subscribe► Subscribe
Sunovion Pharms IncUTIBRONglycopyrrolate ; indacaterol maleatePOWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Sunovion Pharms IncAPTIOMeslicarbazepine acetateTABLET;ORAL022416-001Nov 8, 2013RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms IncAPTIOMeslicarbazepine acetateTABLET;ORAL022416-004Nov 8, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Sunovion Pharms IncLATUDAlurasidone hydrochlorideTABLET;ORAL200603-003Dec 7, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Sunovion Pharms IncUTIBRONglycopyrrolate ; indacaterol maleatePOWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Sunovion Pharms IncAPTIOMeslicarbazepine acetateTABLET;ORAL022416-004Nov 8, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Sunovion Pharms IncAPTIOMeslicarbazepine acetateTABLET;ORAL022416-003Nov 8, 2013RXYesNo► Subscribe► SubscribeYY► Subscribe
Sunovion Pharms IncUTIBRONglycopyrrolate ; indacaterol maleatePOWDER;INHALATION207930-001Oct 29, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Sunovion Pharms IncLATUDAlurasidone hydrochlorideTABLET;ORAL200603-002Oct 28, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Sunovion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
Sunovion Pharms IncUTIBRONglycopyrrolate ; indacaterol maleatePOWDER;INHALATION207930-001Oct 29, 2015► Subscribe► Subscribe
Sunovion Pharms IncLUNESTAeszopicloneTABLET;ORAL021476-002Dec 15, 2004► Subscribe► Subscribe
SunovionBROVANAarformoterol tartrateSOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
SunovionBROVANAarformoterol tartrateSOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
SunovionBROVANAarformoterol tartrateSOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
Sunovion Pharms IncLUNESTAeszopicloneTABLET;ORAL021476-001Dec 15, 2004► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
SunovionBROVANAarformoterol tartrateSOLUTION;INHALATION021912-001Oct 6, 2006► Subscribe► Subscribe
SunovionXOPENEX HFAlevalbuterol tartrateAEROSOL, METERED;INHALATION021730-001Mar 11, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SUNOVION drugs

Drugname Dosage Strength Tradename Submissiondate
lurasidone hydrochlorideTablets20 mg, 40 mg, 60 mg, 80 mg, and 120 mgLATUDA10/28/2014
arformoterol tartrateInhalation SolutionEq. 0.015 mg base/2 mLBROVANA10/1/2009
eszopicloneTablets1 mg, 2 mg and 3 mgLUNESTA12/15/2008

Non-Orange Book Patents for Sunovion

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,223,748Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
7,541,022Pharmaceutical formulations for dry powder inhalers► Subscribe
8,436,017Beta-2-adrenoreceptor agonists► Subscribe
7,605,260Process for producing imide compound► Subscribe
5,780,632 Imide derivatives and their production and use► Subscribe
8,101,160Formulations for use in inhaler devices► Subscribe
8,871,274Pharmaceutical formulations for dry powder inhalers► Subscribe
9,566,239Pharmaceutical formulations for dry powder inhalers► Subscribe
8,258,139Method of treatment for mental disorders► Subscribe
6,884,794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Sunovion Drugs

Country Document Number Estimated Expiration
European Patent Office2298279► Subscribe
Czech Republic302403► Subscribe
Spain2378990► Subscribe
Japan2013155208► Subscribe
Australia5834301► Subscribe
Mexico2010004323► Subscribe
Hong Kong1045837► Subscribe
Australia2705900► Subscribe
Canada2271004► Subscribe
European Patent Office1337239► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Sunovion Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014000092Germany► SubscribePRODUCT NAME: LURASIDON, INSBESONDERE EINE PHARMAZEUTISCH VERTRAEGLICHE SALZFORM UND IM SPEZIELLEN DAS HYDROCHLORIDSALZ DAVON; REGISTRATION NO/DATE: EU/1/14/913/001-021 20140321
0583Netherlands► SubscribePRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE AFGELEIDEN DAARVAN; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
1267866/02Switzerland► SubscribeFORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
2014034Lithuania► SubscribePRODUCT NAME: LURASIDONUM; REGISTRATION NO/DATE: EU/1/14/913 20140321
2013 00015Denmark► SubscribePRODUCT NAME: GLYCOPYRRONIUM ELLER ET SALT DERAF, HERUNDER GLYCOPYRRONIUMBROMID; REG. NO/DATE: EU/1/12/788/001-006 20121003
0690Netherlands► SubscribePRODUCT NAME: LURASIDON HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/913 20140327
2013 00015Denmark► Subscribe
90057-5Sweden► SubscribePRODUCT NAME: LURASIDONE, OPTIONALLY IN THE FORM OF LURASIDONE HYDROCHLORIDE; REG. NO/DATE: EU/1/14/913 20140327
2013000029Germany► SubscribePRODUCT NAME: GLYKOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
00583Netherlands► SubscribePRODUCT NAME: GLYCOPYRRONIUM EN ALLE DOOR HET BASISOCTROOI BESCHERMDE; REGISTRATION NO/DATE: EU/1/12/788/001-006 20120928
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
AstraZeneca
Novartis
Queensland Health
Julphar
US Department of Justice
McKesson
Covington
Healthtrust
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot